FDA approves Lilly's Foundayo, the first GLP-1 pill with no food or water restrictions
The FDA approved Eli Lilly's once-daily orforglipron (Foundayo), the first GLP-1 pill that can be taken any time of day, for adults with obesity or overweight and a related condition.
The FDA has approved orforglipron, a once-daily pill that Eli Lilly will sell as Foundayo, for adults with obesity or with overweight and a weight-related condition. Lilly says it is the company’s second obesity medicine and the first GLP-1 in pill form that can be taken at any time of day, with or without food or water.
How it is taken
The other GLP-1 pill on the market, oral semaglutide, has to be taken on an empty stomach with a small sip of water, followed by a wait before eating or drinking. According to Lilly, Foundayo has no such timing rules and is swallowed whole. It is a daily pill rather than a weekly injection.
What the trial reported
In Lilly’s ATTAIN-1 trial, adults on the highest dose lost about 12.4 percent of their body weight on average, roughly 27 pounds, alongside a reduced-calorie diet and more physical activity. Lilly describes that as the strongest weight-loss result reported so far for a GLP-1 pill. The figure is below what the injectable GLP-1s reported in their own trials.
Availability and cost
Lilly says Foundayo will be available first through its LillyDirect service, with pharmacies and telehealth providers to follow. The company set the price at $149 a month for people paying out of pocket and $25 a month for those with commercial insurance that covers it.
Worth knowing
Foundayo is a prescription medicine. Whether it is appropriate, the dose, and its risks and side effects are matters for the label and a prescriber. The weight-loss figures above are from Lilly and its ATTAIN-1 trial.
General information, not medical advice. Care decisions are between you and a licensed prescriber.